Uni-Bio Science Group

Uni-Bio Science Group EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Uni-Bio Science Group (690.HK) as of Oct 16, 2026 is 21.96. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 15.65 — a change of 40.28% (higher).

EV/FCF

21.96

YoY

40.28%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Uni-Bio Science Group is 2024 21.96 . EV/FCF (Enterprise Value to Free Cash Flow) of Uni-Bio Science Group was 2023 15.65 . It decreases by 40.28% higher compared to the previous year.

The Uni-Bio Science Group EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2017
-5.95 HKD
Jan 1, 2018
-7.19 HKD
Jan 1, 2019
-14.97 HKD
Jan 1, 2020
-22.04 HKD
Jan 1, 2021
168.25 HKD
Jan 1, 2022
30.13 HKD
Jan 1, 2023
15.65 HKD
Jan 1, 2024
21.96 HKD
The Uni-Bio Science Group EV/FCF history
YEAREV/FCFYoY
21.96+40.28%
15.65-48.05%
30.13-82.09%
168.25-863.30%
-22.04+47.20%
-14.97+108.27%
-7.19+20.75%
-5.95-57.34%
-13.96+10.69%
-12.61+84.52%
-6.83—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Uni-Bio Science Group Stock analysis

What does Uni-Bio Science Group do? Uni-Bio Science Group Ltd, listed on the Hong Kong Stock Exchange under ticker 690.HK with ISIN KYG9198H1406, operates in the Health Care sector within the Biotechnology industry. The company, which completed its IPO on November 12, 2001, employs 340 full-time staff. Uni-Bio Science Group functions through four business segments. The In-house Chemical Pharmaceutical Products segment focuses on manufacturing and selling proprietary chemical pharmaceutical products, including the product named Pinapu. The In-house Biological Pharmaceutical Products segment handles the production and distribution of biological pharmaceutical products such as GeneTime and GeneSoft. The In-house Biological Pipeline segment is dedicated to advancing the industrialization of its biological pipeline, featuring products like Uni-E4 and Uni-PTH. The Third-party Pharmaceutical Products segment manages the sales of pharmaceutical products from external suppliers. The company's headquarters location is not publicly specified, and its official website is www.uni-bioscience.com. Uni-Bio Science Group's business model integrates in-house development with third-party product distribution, targeting both chemical and biological pharmaceutical markets. The company's operational structure reflects a diversified approach to pharmaceutical research, development, and commercialization, though specific details about its research pipeline, market reach, or financial performance are not provided in the available information. Uni-Bio Science Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Uni-Bio Science Group stock

EV/FCF (Enterprise Value to Free Cash Flow) of Uni-Bio Science Group is 21.96 in 2024.

EV/FCF (Enterprise Value to Free Cash Flow) of Uni-Bio Science Group changed from 15.65 to 21.96, representing a 40.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Uni-Bio Science Group since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Uni-Bio Science Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Uni-Bio Science Group

All Key Metrics — Uni-Bio Science Group